Indivior PLC Share Price Nasdaq

Equities

INDV

GB00BN4HT335

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 14/06/2024 BST 5-day change 1st Jan Change
16.53 USD +1.47% Intraday chart for Indivior PLC +1.10% +8.25%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 1.27B 99.99B Sales 2025 * 1.42B 112B Capitalization 2.24B 177B
Net income 2024 * 268M 21.13B Net income 2025 * 341M 26.89B EV / Sales 2024 * 1.54 x
Net cash position 2024 * 287M 22.63B Net cash position 2025 * 587M 46.28B EV / Sales 2025 * 1.16 x
P/E ratio 2024 *
8.99 x
P/E ratio 2025 *
6.9 x
Employees 1,000
Yield 2024 *
-
Yield 2025 *
-
Free-Float 96.69%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.47%
1 week+1.10%
Current month-9.77%
1 month-5.70%
3 months-20.34%
6 months+0.85%
Current year+8.25%
More quotes
1 week
16.10
Extreme 16.1
17.09
1 month
16.10
Extreme 16.1
18.59
Current year
15.00
Extreme 15
23.22
1 year
14.38
Extreme 14.3809
24.90
3 years
9.90
Extreme 9.9
26.50
5 years
2.13
Extreme 2.13
26.50
10 years
1.75
Extreme 1.75
33.60
More quotes
Managers TitleAgeSince
Chief Executive Officer - 31/12/11
Director of Finance/CFO - 31/12/11
Compliance Officer - 30/09/18
Members of the board TitleAgeSince
Chairman 65 31/10/19
Director/Board Member 64 31/05/22
Director/Board Member 61 23/03/21
More insiders
Date Price Change Volume
14/06/24 16.53 +1.47% 48,997
13/06/24 16.29 -3.32% 55,273
12/06/24 16.85 -0.12% 31,936
11/06/24 16.87 -0.59% 41,208
10/06/24 16.97 +3.79% 60,892

Delayed Quote Nasdaq, June 14, 2024 at 09:00 pm

More quotes
Indivior PLC is a pharmaceutical company. The Company develops medicines to treat addiction and serious mental illnesses. The Company focuses on building a portfolio of opioid dependence treatments. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of addiction, including alcohol use disorder. Its product pipeline focuses on development and discovery of non-opioid treatment strategies for opioid use disorder (OUD), as well as therapies to address the needs of people suffering from alcohol, stimulant, and cannabis use disorders. Its Sublocade, Subutex, and Suboxone are used for the treatment of opioid use disorder (OUD). Perseris is used for the treatment of Schizophrenia. The Company's pipeline products include AEF0117, INDV-2000, INDV-1000, RBP-6000, RBP-7000, Buprenorphine Sublingual and Naloxone Film, and Buprenorphine and Naloxone Sublingual Tablet. Its pipeline also includes the Orexin-1 Receptor Antagonist Program.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
16.71 USD
Average target price
30.86 USD
Spread / Average Target
+84.63%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW